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Abstract
Background—Several clusters of serogroup C meningococcal disease among men who have sex 
with men (MSM) have been reported in the United States in recent years. The epidemiology and 
risk of meningococcal disease among MSM is not well described.
Methods—All meningococcal disease cases among men aged 18–64 years reported to the 
National Notifiable Disease Surveillance System between January 2012 and June 2015 were 
reviewed. Characteristics of meningococcal disease cases among MSM and men not known to be 
MSM (non-MSM) were described. Annualized incidence rates among MSM and non-MSM were 
compared through calculation of the relative risk and 95% confidence intervals. Isolates from 
meningococcal disease cases among MSM were characterized using standard microbiological 
methods and whole-genome sequencing.
Results—Seventy-four cases of meningococcal disease were reported among MSM and 453 
among non-MSM. Annualized incidence of meningococcal disease among MSM was 0.56 cases 
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per 100 000 population, compared to 0.14 among non-MSM, for a relative risk of 4.0 (95% 
confidence interval [CI], 3.1–5.1). Among the 64 MSM with known status, 38 (59%) were 
infected with human immunodeficiency virus (HIV). HIV-infected MSM had 10.1 times (95% CI, 
6.1–16.6) the risk of HIV-uninfected MSM. All isolates from cluster-associated cases were 
serogroup C sequence type 11.
Conclusions—MSM are at increased risk for meningococcal disease, although the incidence of 
disease remains low. HIV infection may be an important factor for this increased risk. Routine 
vaccination of HIV-infected persons with a quadrivalent meningococcal conjugate vaccine in 
accordance with Advisory Committee on Immunization Practices recommendations should be 
encouraged.
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Meningococcal disease is a serious bacterial infection caused by Neisseria meningitidis and 
can lead to high morbidity and mortality rates [1, 2]. During 2010–2015, clusters of 
serogroup C meningococcal disease among men who have sex with men (MSM) were 
reported in the United States in New York City (NYC), Los Angeles County (LAC), and 
Chicago, disproportionately affecting MSM with human immunodeficiency virus (HIV) 
infection [3]. In addition, clusters among MSM have been reported in Berlin and Paris [4, 5]. 
However, little is known about the overall burden or risk of meningococcal disease among 
MSM, including HIV-infected MSM, in the United States.
MSM have not historically been considered at increased risk for meningococcal disease in 
the United States and are not routinely vaccinated against meningococcal disease outside of 
the adolescent quadrivalent meningococcal conjugate vaccination program unless certain 
underlying conditions are present [1]. However, HIV infection is increasingly recognized as 
a risk factor for meningococcal disease, and in June 2016, the Advisory Committee on 
Immunization Practices (ACIP) recommended routine quadrivalent meningococcal 
conjugate vaccine for all HIV-infected persons aged ≥2 months [6].
In this evaluation, we estimate the incidence of meningococcal disease among MSM in the 
United States, describe characteristics of MSM with meningococcal disease, estimate the 
risk of meningococcal disease by HIV status among MSM compared to men not known to 
be MSM, and describe the molecular characteristics of disease-causing strains to better 
understand the epidemiology of meningococcal disease in this population.
METHODS
Surveillance and Descriptive Epidemiology
In the United States, meningococcal disease cases are reported to the Centers for Disease 
Control and Prevention (CDC) through the National Notifiable Disease Surveillance System 
(NNDSS) and are classified by state and local public health personnel according to the 
Council of State and Territorial Epidemiologists case definition [7]. As sex of 
meningococcal disease patients’ sex partners is not collected through NNDSS, CDC issued 
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requests for this information in 2013 and 2015 through the Epidemic Information Exchange 
(Epi-X), CDC’s system for rapid and secure exchange of public health information between 
CDC and state and local health departments, and received responses from health 
departments from all 50 states and the District of Columbia. State and local health 
departments were asked to identify MSM among meningococcal patients aged 18–64 years 
prospectively during case investigations. In addition, health departments conducted 
retrospective reviews of cases reported since 2012, identifying men as MSM based on 
interviews completed during the investigation of the case or disclosures of sexual contact 
with another man during contact tracing.
For patients identified as MSM, supplemental demographic, laboratory, and risk factor data, 
such as HIV status, smoking, and drug use were abstracted from case investigation records 
and linked to the patient record in NNDSS for analysis. Additional data on sexual behaviors, 
such as multiple or anonymous sex partners, were collected by state and local health 
departments during the investigation of cases that occurred as part of a cluster. HIV infection 
status and risk behavior data were not available for men not known to be MSM. Cases were 
classified as MSM if identified as such during case investigation or as non-MSM if not 
known to be MSM. MSM cases were further classified into jurisdiction-specific groups 
(NYC, LAC, and Chicago) if an outbreak or cluster of meningococcal disease among MSM 
was reported by a health department during the observation period, or as sporadic cases 
reported outside of the jurisdictions with reported outbreaks or clusters. For these 
jurisdictions, all cases with residence in that jurisdiction were included in jurisdiction-
specific estimates, regardless of serogroup or molecular linkage to the cluster. Cases that 
were epidemiologically linked to an outbreak or cluster but with residence outside of the 
jurisdiction were not included.
Laboratory Methods
Available isolates and clinical specimens from MSM cases were sent to the CDC’s Bacterial 
Meningitis Laboratory where confirmatory testing and molecular typing for N. meningitidis 
were performed. Serogroup was determined by slide agglutination and/or serogroup-specific 
real-time polymerase chain reaction.
The genomes of all isolates were sequenced using Illumina technology and assembled as 
described in Kretz et al [8]. Multilocus sequence typing (MLST) alleles were identified 
based on a BLAST search of the assembled genomes against the PubMLST allele lists [9]. 
Protein sequences were likewise typed according to PubMLST sequence collection. PorA, 
PorB, and FetA were classified according to their respective variable regions, NadA was 
categorized by the Novartis convention of variant and peptide ID [10], NhbA was identified 
by PubMLST peptide identifier, and FHbp was identified by the PubMLST peptide identifier 
and the Pfizer peptide identifier (subfamilies A and B).
For each comparison of genome-wide similarity, core single- nucleotide polymorphisms 
(SNPs) were identified using kSNP v3 software [11], with a kmer length of 25, and SNP 
allele differences between strains were calculated using pairwise comparison. SNPs were 
then compared across all genomes. A maximum likelihood phylogenetic tree was built based 
Folaranmi et al. Page 3
Clin Infect Dis. Author manuscript; available in PMC 2017 December 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
on core SNPs, using MEGA6 [12], the Tamura-Nei substitution model with 500 bootstrap 
iterations.
Statistical Analysis
A descriptive analysis of demographic characteristics, clinical features, and outcomes was 
conducted. Significant differences (P < .05) among MSM and non-MSM were assessed 
through χ2 or Fisher exact test. Annualized incidence was calculated as the number of 
meningococcal disease cases per 100 000 men aged 18–64 years per year using national and 
jurisdiction-specific population estimates for all men, all MSM, HIV-infected and -
uninfected MSM, and non-MSM. The populations of men aged 18–64 years in the United 
States and by jurisdiction were derived from the 2012 American Community Survey [13]. 
The proportion of males who are MSM, defined as sex with another man in the past 5 years, 
was estimated to be 3.9% nationwide [14], and the proportions of MSM in LAC, NYC, 
Chicago, and all other United States jurisdictions were estimated to be 6.8%, 7.3%, 6.6%, 
and 3.3%, respectively [15]. The proportions of HIV-infected MSM nationwide and by 
jurisdiction were derived from national and jurisdiction-specific surveillance reports [16–
19]. The overall and jurisdiction-specific numbers of MSM, HIV-infected MSM, HIV-
uninfected MSM, and non-MSM were calculated by multiplying the male population aged 
18–64 years by the estimated proportion of MSM and by HIV status. Relative risk (RR) and 
95% confidence intervals (CIs) of meningococcal disease among MSM were calculated by 
comparing the annualized incidence of MSM and non-MSM cases. Case-fatality ratios 
(CFR) were calculated by dividing the number of cases with death reported as the outcome 
by the total number of cases with known outcome within each category. Data were analyzed 
using SAS software version 9.3 (SAS Institute, Cary, North Carolina).
Ethical Considerations
All data were de-identified prior to transmission and analysis at CDC. This evaluation was 
determined to be public health practice and exempted from full review by the CDC 
Institutional Review Board.
RESULTS
Demographics, Surveillance, and Clinical Characteristics
Between 1 January 2012, and 30 June 2015, 527 cases of meningococcal disease in men 
aged 18–64 years were reported through NNDSS. Among these, 74 (14.0%) were identified 
as occurring in MSM, with 46 (62.6%) cases among MSM reported in jurisdictions that 
experienced a cluster of meningococcal disease: 23 cases in NYC, 14 in LAC, and 9 in 
Chicago. Twenty-eight sporadic cases among MSM were reported from 19 states. The 
remaining 453 cases (86.0%) were reported among non-MSM from 46 states and the District 
of Columbia (Figure 1).
The largest proportion of meningococcal disease cases reported as MSM occurred among 
men aged 26–35 years (43.2%) and for non-MSM cases among men aged 18–25 years 
(31.4%). Race and ethnicity among meningococcal disease patients varied by jurisdiction 
(Table 1). Among infections with a known serogroup, N. meningitidis serogroup C 
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accounted for 62 of 73 (84.9%) infections in MSM compared to 98 of 381 (25.7%) 
infections in non-MSM patients. HIV infection was reported in 38 of 64 (59.4%) MSM with 
known status. No data on CD4 count or viral load were available. While MSM cases overall 
had higher CFRs than non-MSM cases (32.4% vs 23.5%), the difference was not statistically 
significant (P = .112) (Table 1). No association between HIV status and fatal outcome (P = .
558) was observed among MSM.
Among all MSM with available information, 20 of 63 (31.7%) patients reported smoking 
and 26 of 53 (49.1%) reported use of recreational drugs including marijuana. Of the 46 
cluster-associated MSM cases from NYC, LAC, and Chicago, 31 patients had sexual 
partnership data available, of whom 14 (45.2%) reported multiple sex partners or 
engagement in anonymous sex. Of the 32 cluster-associated cases from NYC and Chicago, 
23 had data available related to the use of online dating applications or websites to meet 
partners; 14 of 23 (60.9%) patients reported using these methods.
Genomic Characterization and Diversity of the Isolates
Whole-genome sequencing analysis was performed to assess the genetic relatedness of 37 
isolates from cluster and sporadic cases. All 24 isolates from cluster-associated cases in 
Chicago (n = 5), NYC (n = 14), and LAC (n = 5) belonged to sequence type (ST) 11 and 
clonal complex (CC) 11. Of the 13 sporadic isolates, there were 9 ST11/CC11, 2 
ST4221/CC unassigned, 1 ST1679/CC35, and 1 ST1466/CC174 (Table 2). The Chicago 
isolates formed a distinct clade in the phylogenetic tree, with 0–10 core SNPs difference out 
of the 13 026 core SNPs identified among the 37 isolates. All but 3 NYC isolates clustered 
together in 1 phylogenetic group, with 0–234 SNPs difference between the isolates within 
the phylogenetic group and 0–337 SNPs difference between all NYC isolates. Three isolates 
from LAC are very closely related to each other, with 1–3 SNPs difference, while the other 2 
LAC isolates are more distantly related, with 1–685 SNPs difference between all LAC 
isolates (Figure 2). Nine CC11 isolates from the sporadic cases were either in one of the 
clades associated with MSM clusters or closely related to these clades. All non-CC11 
isolates formed distinct phylogenetic groups. The SNP difference among the sporadic 
isolates ranged from 2 to 7256 SNPs.
Relative Risk for Meningococcal Disease Among Men Who Have Sex With Men
The annualized incidence of meningococcal disease among MSM overall was 0.56 cases per 
100 000 persons compared to 0.14 cases per 100 000 persons among all non-MSM, for a 
relative risk (RR) of 4.0 (95% CI, 3.1–5.1; P < .001) (Table 3). In areas outside of where 
meningococcal disease clusters occurred, MSM had 1.9 (95% CI, 1.3–2.8; P < .001) times 
the risk of meningococcal disease compared to non-MSM, while the risk of meningococcal 
disease among MSM was 14.6–31.8 times that of non-MSM in jurisdictions where clusters 
occurred (Table 3). HIV-infected MSM had 10.1 times (95% CI, 6.1–16.6; P < .001) the risk 
of meningococcal disease compared to HIV-uninfected MSM, with the highest RR occurring 
in areas where no disease cluster was identified (RR, 12.7; 95% CI, 5.1–31.9; P < .001) 
(Table 4). Though HIV status of non-MSM is unknown, when HIV-uninfected MSM were 
compared to non-MSM, HIV-uninfected MSM had 1.6 times (95% CI, 1.1–2.4; P = .016) the 
risk of meningococcal disease. However, when stratified by jurisdictional area, this increase 
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was observed primarily in jurisdictions where clusters were identified (RR, 6.7–18.3), 
compared with RR of 0.6 (95% CI, .3–1.2) in jurisdictions where no clusters were identified 
(Table 3).
DISCUSSION
Since the first reported outbreak of meningococcal disease among MSM in 2001 in Toronto, 
several outbreaks or clusters have been reported among MSM in Europe and the United 
States [3, 20, 21]. Determining the need for routine meningococcal vaccination of MSM in 
nonoutbreak settings has been challenging given the lack of data on the burden and risk of 
disease in this population in the United States. In this evaluation, we demonstrate that 
although the incidence is low, the relative risk of meningococcal disease is higher among 
MSM than the non-MSM male population in the United States, with HIV infection 
identified as a likely factor for this increased risk observed among MSM in sporadic settings. 
Additionally, the majority of cases among MSM are due to serogroup C and occur among 
age groups not currently recommended to receive quadrivalent meningococcal conjugate 
vaccine through the routine adolescent program.
Evaluations in the United States, England, and South Africa demonstrate relative risks of 
4.5–24.0 for meningococcal disease among HIV-infected compared to HIV-uninfected 
persons, with the highest risk in persons with high viral load or low CD4 count [22–24]. 
Disentangling the independent effects of HIV infection and being MSM on the risk of 
meningococcal disease is challenging, given the lack of data on HIV status of non-MSM. In 
addition, 59% of MSM in our evaluation were HIV-infected, compared to a national HIV 
prevalence of 21.6% among MSM [25]. However, given that the risk of meningococcal 
disease in the sporadic setting is elevated only among HIV-infected MSM, HIV may be an 
important driver for increased risk of disease among MSM in settings where clusters of 
disease have not been reported. On the other hand, in meningococcal disease clusters, risk 
was elevated for both HIV-infected and HIV-uninfected MSM, suggesting that additional 
factors may be involved in the occurrence of meningococcal disease clusters among MSM.
The sex of a meningococcal disease patient’s sex partners is likely a proxy for other 
unmeasured risk factors contributing to the development of meningococcal disease clusters 
among MSM. In the NYC and Chicago clusters, for example, the majority of cases among 
MSM were black and geographically clustered in certain sections of the cities, suggesting 
that increased transmission occurred among common social networks. Additionally, in this 
evaluation, a high prevalence of behaviors were reported that may favor transmission of, or 
increased susceptibility to, N. meningitidis in this population. Among MSM patients with 
known information, 31.7% smoke tobacco, compared to 17.8% of adults in the United States 
[26]. Nearly half (48.1%) of MSM patients reported use of recreational drugs, including 
marijuana, compared to the US average of 10.2% [27]. Among cluster-associated cases, a 
high proportion of patients reported sexual activity with multiple and/or anonymous partners 
or use of online dating applications or websites to find sex partners. However, the lack of a 
comparison group limits the ability to determine risk factors for meningococcal disease 
among MSM and identify MSM subgroups at greatest risk. No known clusters of 
meningococcal disease have occurred among other sexual minority groups, such as women 
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who have sex with women, in the United States. Additional evaluations to identify risk 
factors will be necessary to inform preventative strategies among MSM.
A high CFR (32% overall) was observed among MSM, although it was not statistically 
different from that of non-MSM. While reports from the literature in the general population 
are mixed, with lower meningococcal disease CFR among HIV-infected persons compared 
with HIV-uninfected persons in the United States and United Kingdom [22, 24], and higher 
CFR among HIV-infected compared with HIV-uninfected persons in South Africa [23], we 
did not observe an association between HIV infection and case outcome among MSM. The 
high CFR among MSM in our evaluation may be related to the large proportion of cases due 
to serogroup C ST11, which is known to be a more virulent strain [28, 29].
All reported meningococcal clusters among MSM globally to date have been due to 
serogroup C ST11/CC11 [3, 20, 21]. Molecular characterization suggests that the strains 
responsible for clusters of meningococcal disease among MSM reported in this analysis may 
have come from a common ancestor and further diverged over time under different 
environmental conditions. Additional evaluations of carriage and disease-causing strains 
among MSM populations using whole-genome sequencing–based methods are important to 
understand disease transmission and the molecular epidemiology of meningococcal disease 
in this population.
Several considerations regarding the estimated risk and risk factors for meningococcal 
disease among MSM should be noted. First, ascertainment of the sex of sex partners of 
meningococcal disease patients during case investigations is not systematic across state 
health departments and is dependent on disclosure by the patient. Thus, the risk of 
meningococcal disease among MSM may be underestimated in this evaluation due to 
misclassification. Likewise, HIV status and behavioral risk factors are not uniformly 
collected during case investigations, limiting the completeness of this information and thus 
the ability to identify subgroups at greatest risk. Additionally, meningococcal disease 
incidence estimates among MSM and by HIV status rely on the accuracy of the 
denominators available. While jurisdiction-specific estimates were used where 
meningococcal disease clusters occurred, the denominator for sporadic cases outside of 
these jurisdictions was based on a standard proportion of MSM, whereas true proportions of 
MSM among the male population likely vary considerably at the local level.
The increased risk of meningococcal disease among HIV-infected MSM in this evaluation 
provides further support for the recent ACIP recommendation for routine vaccination of all 
HIV-infected persons aged ≥2 months with a quadrivalent meningococcal conjugate vaccine. 
While HIV-uninfected MSM have a 1.6-fold increased risk compared to non-MSM, this 
increased risk is lower than that observed among other at-risk groups in whom routine 
quadrivalent meningococcal conjugate vaccine is recommended, such as persons with 
asplenia or complement component deficiencies, who have up to a 10 000-fold increased 
risk for meningococcal disease [1]. As routine vaccination of MSM with a quadrivalent 
meningococcal vaccine is not currently recommended by ACIP, high uptake of 
meningococcal disease among HIV-infected persons offers an opportunity to also potentially 
impact the risk of meningococcal disease among the MSM population as a whole.
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Although rare, cases and clusters of meningococcal disease among MSM continue to occur 
in the United States. While this evaluation demonstrates the increased risk of disease among 
MSM, further study is needed to better understand transmission and risk factors in this 
population to inform public health prevention and response strategies. Ascertainment of HIV 
status of all meningococcal disease patients and the sex of sex partners of patients aged ≥16 
years will be important to understand the true burden of disease in this population as well as 
to rapidly detect meningococcal disease clusters among MSM at the local level. In the 
meantime, clinicians and public health authorities should continue to increase awareness of 
meningococcal disease among MSM, identify vaccination strategies and other public health 
response measures to protect MSM during outbreaks of meningococcal disease in this 
population, and encourage routine vaccination of all HIV-infected MSM with a quadrivalent 
meningococcal conjugate vaccine.
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Figure 1. 
Number and proportion of meningococcal disease cases by month among men who have sex 
with men (MSM) and men not known to be MSM (non-MSM) aged 18–64 years, January 
2012–June 2015. Abbreviations: LAC, Los Angeles County; MSM, men who have sex with 
men; NYC, New York City.
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Figure 2. 
Molecular phylogenetic analysis based on whole-genome sequencing from sporadic and 
cluster-associated meningococcal isolates among men who have sex with men aged 18–64 
years, January 2012–June 2015. The maximum likelihood tree was based on the Tamura-Nei 
model. The tree is drawn to scale with branch lengths measured in the number of 
substitution per site. Internal nodes are labeled with bootstrap values (500 iterations). The 
scale bar is based on the 13 026 positions in the core single-nucleotide polymorphism (SNP) 
matrix. Labels represent the location of the outbreak and the year collected, FAM18 and 
MC58 as outgroups. A distance scale bar is shown at the bottom left. *Cluster-associated 
cases refers to 2 cases epidemiologically linked to the Chicago cluster who were not 
residents of Chicago. Abbreviations: LAC, Los Angeles County; NYC, New York City.
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